Abstract
HMG-CoA reductase inhibitors (statins) are effective lipid-lowering drugs widely used in patients with dyslipidemia at risk of cardiovascular diseases. Primary and secondary prevention studies have revealed a significant reduction of risk for cardiovascular diseases. However, recent studies have demonstrated that statins have direct vascular effects (pleiotropic effects) independent of lipid-lowering action. Vascular remodeling, defined as changes in size and / or structure of adult vasculature, not only allows physiological adaptation and healing but also underlines the pathogenesis of major cardiovascular diseases. Vascular remodeling can be inward, occlusive, and outward. Various cardiovascular diseases probably represent a terminal phenotype of such vascular remodeling. In this review, we will focus on the basic actions and clinical implications of statin therapy to each type of vascular remodeling in response to various stimuli.
Keywords: statin, vascular remodeling, cardiovascular disease, pleiotropic effect
Current Vascular Pharmacology
Title: Therapeutic Value of Statins for Vascular Remodeling
Volume: 1 Issue: 3
Author(s): Hirotaka Nagashima and Hiroshi Kasanuki
Affiliation:
Keywords: statin, vascular remodeling, cardiovascular disease, pleiotropic effect
Abstract: HMG-CoA reductase inhibitors (statins) are effective lipid-lowering drugs widely used in patients with dyslipidemia at risk of cardiovascular diseases. Primary and secondary prevention studies have revealed a significant reduction of risk for cardiovascular diseases. However, recent studies have demonstrated that statins have direct vascular effects (pleiotropic effects) independent of lipid-lowering action. Vascular remodeling, defined as changes in size and / or structure of adult vasculature, not only allows physiological adaptation and healing but also underlines the pathogenesis of major cardiovascular diseases. Vascular remodeling can be inward, occlusive, and outward. Various cardiovascular diseases probably represent a terminal phenotype of such vascular remodeling. In this review, we will focus on the basic actions and clinical implications of statin therapy to each type of vascular remodeling in response to various stimuli.
Export Options
About this article
Cite this article as:
Nagashima Hirotaka and Kasanuki Hiroshi, Therapeutic Value of Statins for Vascular Remodeling, Current Vascular Pharmacology 2003; 1 (3) . https://dx.doi.org/10.2174/1570161033476592
DOI https://dx.doi.org/10.2174/1570161033476592 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Predictors of Ominous Outcome in Infants who Undergo Cardiac Surgery and Cardiopulmonary By-Pass: S100B Protein
CNS & Neurological Disorders - Drug Targets Evaluation of Fourteen Aurone Derivatives as Potential Anti-Cancer Agents
Current Pharmaceutical Biotechnology Anthracycline-Induced Cardiotoxicity
Cardiovascular & Hematological Agents in Medicinal Chemistry A Perspective on Quantum Mechanics Calculations in ADMET Predictions
Current Topics in Medicinal Chemistry The Application of Rational Design on Phospholipase A2 Inhibitors
Current Medicinal Chemistry Dendritic Cells in Pathogenesis of COPD
Current Pharmaceutical Design Role of Heart Rate Reduction in the Management of Myocarditis
Current Pharmaceutical Design Editorial (Thematic Issue: Novel Data on the Pathogenesis of Atherosclerosis, Treatment Targets, and New Therapeutic Interventions in Lipid-Related Cardiovascular Risk Factors)
Current Pharmaceutical Design The Role of Oxidative Stress in Methamphetamine and MDMA-induced Toxicity
Mini-Reviews in Organic Chemistry Effects of Physical Exercise on Inflammatory Markers of Atherosclerosis
Current Pharmaceutical Design Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Psychosocial Implications During Adolescence for Infant Heart Transplant Recipients
Current Cardiology Reviews Heart Failure in Chronic Myocarditis: A Role for microRNAs?
Current Genomics Critical Determinants of Cardiovascular Risk in Rheumatoid Arthritis
Current Pharmaceutical Design Cathinone Neurotoxicity (“The “3Ms”)
Current Neuropharmacology Hybrid Therapy in the Management of Atrial Fibrillation
Current Cardiology Reviews Patent Selections
Recent Patents on Biotechnology Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design Role of Angiotensin-1-Receptor Blockers In Cardiorenal Disease
Current Drug Therapy